Formulation and Optimization of Sustained-Release Diclofenac Microspheres for Orally Disintegrating Tablets.

IF 4.5 Q3 MATERIALS SCIENCE, BIOMATERIALS
International Journal of Biomaterials Pub Date : 2025-10-15 eCollection Date: 2025-01-01 DOI:10.1155/ijbm/5552692
Meron Amdework, Fantahun Molla, Afewerk Getachew
{"title":"Formulation and Optimization of Sustained-Release Diclofenac Microspheres for Orally Disintegrating Tablets.","authors":"Meron Amdework, Fantahun Molla, Afewerk Getachew","doi":"10.1155/ijbm/5552692","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Chronic musculoskeletal problems necessitate long-term symptomatic treatments. In such cases, diclofenac (D<sub>fNa</sub>) is frequently prescribed. However, its demand for frequent administration might result in serious dose-dependent complications. Furthermore, most patients with these illnesses are elderly and may have difficulty swallowing. Such factors can contribute to patients' noncompliance. Therefore, this study aimed to develop a sustained-release orally disintegrating D<sub>fNa</sub> tablet using locally accessible excipients.</p><p><strong>Methods: </strong>D<sub>fNa</sub> microspheres were prepared using the emulsion solvent evaporation technique. Several parameters, including drug-to-polymer ratio (DPR), stirring speed (SS), internal phase volume, and polyethylene glycol content, were explored for their effect on microsphere characteristics. Significant factors were then selected and further optimized to produce microspheres with desirable responses. Eventually, the optimized microspheres were compressed into orally disintegrating tablets with appropriate excipients through direct compression.</p><p><strong>Results: </strong>Preliminary studies indicated that the DPR and SS significantly influenced the response variables. Consequently, their effects on the selected response variables (entrapment efficiency [EE] and Z) were further optimized. This optimization identified optimal conditions at a DPR of 1:1.41 and SS of 905.17 rpm with a predicted EE (69.44%) and Z (175.33 μm). Confirmation tests indicated that the experimental results are in agreement with the predicted values (a percentage error below 5%). Furthermore, the three confirmation batches showed no significant difference in their characteristics, indicating remarkable reproducibility. The microspheres exhibited a non-Fickian anomalous release mechanism, best described by the Higuchi model. All the orally disintegrating tablets prepared from the microspheres met the USP specifications. However, FT1 (compressed at 10 KN) showed a release profile and kinetics similar to those of the uncompressed microspheres. Therefore, it was selected as the best formulation of D<sub>fNa</sub> in this study.</p><p><strong>Conclusion: </strong>This study successfully formulated microsphere-based sustained-release orally disintegrating D<sub>fNa</sub> tablets that sustained drug release for at least 12 h.</p>","PeriodicalId":13704,"journal":{"name":"International Journal of Biomaterials","volume":"2025 ","pages":"5552692"},"PeriodicalIF":4.5000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12543618/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biomaterials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijbm/5552692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic musculoskeletal problems necessitate long-term symptomatic treatments. In such cases, diclofenac (DfNa) is frequently prescribed. However, its demand for frequent administration might result in serious dose-dependent complications. Furthermore, most patients with these illnesses are elderly and may have difficulty swallowing. Such factors can contribute to patients' noncompliance. Therefore, this study aimed to develop a sustained-release orally disintegrating DfNa tablet using locally accessible excipients.

Methods: DfNa microspheres were prepared using the emulsion solvent evaporation technique. Several parameters, including drug-to-polymer ratio (DPR), stirring speed (SS), internal phase volume, and polyethylene glycol content, were explored for their effect on microsphere characteristics. Significant factors were then selected and further optimized to produce microspheres with desirable responses. Eventually, the optimized microspheres were compressed into orally disintegrating tablets with appropriate excipients through direct compression.

Results: Preliminary studies indicated that the DPR and SS significantly influenced the response variables. Consequently, their effects on the selected response variables (entrapment efficiency [EE] and Z) were further optimized. This optimization identified optimal conditions at a DPR of 1:1.41 and SS of 905.17 rpm with a predicted EE (69.44%) and Z (175.33 μm). Confirmation tests indicated that the experimental results are in agreement with the predicted values (a percentage error below 5%). Furthermore, the three confirmation batches showed no significant difference in their characteristics, indicating remarkable reproducibility. The microspheres exhibited a non-Fickian anomalous release mechanism, best described by the Higuchi model. All the orally disintegrating tablets prepared from the microspheres met the USP specifications. However, FT1 (compressed at 10 KN) showed a release profile and kinetics similar to those of the uncompressed microspheres. Therefore, it was selected as the best formulation of DfNa in this study.

Conclusion: This study successfully formulated microsphere-based sustained-release orally disintegrating DfNa tablets that sustained drug release for at least 12 h.

Abstract Image

Abstract Image

Abstract Image

口腔崩解片双氯芬酸缓释微球的制备与优化。
慢性肌肉骨骼问题需要长期对症治疗。在这种情况下,双氯芬酸(DfNa)是常用的处方。然而,频繁给药可能导致严重的剂量依赖性并发症。此外,大多数患有这些疾病的患者是老年人,可能有吞咽困难。这些因素都可能导致患者不遵医嘱。因此,本研究旨在开发一种使用局部可获得赋形剂的口腔崩解DfNa缓释片。方法:采用乳液溶剂蒸发法制备DfNa微球。考察了药聚合物比(DPR)、搅拌速度(SS)、内相体积、聚乙二醇含量等参数对微球特性的影响。然后选择重要因素并进一步优化,以生产具有理想响应的微球。最终将优化后的微球与合适的辅料直接压缩成口腔崩解片。结果:初步研究表明,DPR和SS对反应变量有显著影响。因此,进一步优化了它们对捕获效率(trap efficiency)和捕集效率(Z)的影响。优化后的最佳工艺条件为DPR为1:1.41,SS为905.17 rpm,预测的EE为69.44%,Z为175.33 μm。验证试验表明,实验结果与预测值一致(误差小于5%)。此外,三个确认批次的特征没有显着差异,表明具有显著的重复性。微球表现出非菲克式的异常释放机制,最好用Higuchi模型来描述。制备的口腔崩解片均符合美国药典标准。然而,FT1(在10 KN下压缩)的释放曲线和动力学与未压缩的微球相似。因此,本研究选择其作为DfNa的最佳配方。结论:本研究成功制备了微球型口腔崩解DfNa缓释片,缓释时间至少为12 h。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Biomaterials
International Journal of Biomaterials MATERIALS SCIENCE, BIOMATERIALS-
CiteScore
4.30
自引率
3.20%
发文量
50
审稿时长
21 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书